Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other equities research analysts have also recently issued reports on TVRD. Barclays set a $5.00 price target on shares of Tvardi Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, October 13th. Lucid Cap Mkts raised shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Raymond James Financial lowered Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Tvardi Therapeutics in a research report on Monday, December 29th. Finally, BTIG Research dropped their target price on Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.50.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $3.72 on Friday. The business’s fifty day moving average price is $4.20 and its two-hundred day moving average price is $15.37. The stock has a market cap of $34.89 million, a PE ratio of -0.39 and a beta of 0.14. Tvardi Therapeutics has a one year low of $3.50 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVRD. JPMorgan Chase & Co. purchased a new position in shares of Tvardi Therapeutics in the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Tvardi Therapeutics during the 2nd quarter worth approximately $43,000. Headlands Technologies LLC purchased a new position in Tvardi Therapeutics in the second quarter valued at approximately $80,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics during the second quarter valued at approximately $92,000. Finally, Squarepoint Ops LLC acquired a new position in Tvardi Therapeutics during the third quarter valued at approximately $318,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.